These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16442835)

  • 1. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.
    Mandal M; Younes M; Swan EA; Jasser SA; Doan D; Yigitbasi O; McMurphey A; Ludwick J; El-Naggar AK; Bucana C; Mills GB; Myers JN
    Oral Oncol; 2006 Apr; 42(4):430-9. PubMed ID: 16442835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
    Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
    Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.
    Mandal M; Kim S; Younes MN; Jasser SA; El-Naggar AK; Mills GB; Myers JN
    Br J Cancer; 2005 May; 92(10):1899-905. PubMed ID: 15870708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B.
    Zeng Q; Chen S; You Z; Yang F; Carey TE; Saims D; Wang CY
    J Biol Chem; 2002 Jul; 277(28):25203-8. PubMed ID: 11994287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
    Amornphimoltham P; Sriuranpong V; Patel V; Benavides F; Conti CJ; Sauk J; Sausville EA; Molinolo AA; Gutkind JS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4029-37. PubMed ID: 15217935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
    Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
    J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
    Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
    Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.
    Cameron S; de Long LM; Hazar-Rethinam M; Topkas E; Endo-Munoz L; Cumming A; Gannon O; Guminski A; Saunders N
    Mol Cancer; 2012 Sep; 11():74. PubMed ID: 23021083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways.
    Lin J; Guan Z; Wang C; Feng L; Zheng Y; Caicedo E; Bearth E; Peng JR; Gaffney P; Ondrey FG
    Clin Cancer Res; 2010 Jan; 16(1):77-87. PubMed ID: 20028744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
    Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
    Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.
    García-Carracedo D; Villaronga MÁ; Álvarez-Teijeiro S; Hermida-Prado F; Santamaría I; Allonca E; Suárez-Fernández L; Gonzalez MV; Balbín M; Astudillo A; Martínez-Camblor P; Su GH; Rodrigo JP; García-Pedrero JM
    Oncotarget; 2016 May; 7(20):29780-93. PubMed ID: 27119232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
    Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
    BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
    Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte chemotactic protein 1 (MCP-1) modulates pro-survival signaling to promote progression of head and neck squamous cell carcinoma.
    Ji WT; Chen HR; Lin CH; Lee JW; Lee CC
    PLoS One; 2014; 9(2):e88952. PubMed ID: 24586454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of KHDC1L promotes the proliferation and inhibits apoptosis in head and neck squamous cell carcinoma.
    Zhang Q; Luo S; Luo Y; Huang Y; Wang Z; Xie X
    Epigenetics; 2023 Dec; 18(1):2175168. PubMed ID: 36734243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.